Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Eleftherios Pelechas, Paraskevi V Voulgari & Alexandros A. Drosos. (2021) Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opinion on Drug Discovery 16:3, pages 227-234.
Read now
Read now
Christophe Richez & Marie-Elise Truchetet. (2020) What value do JAK inhibitors have in treating rheumatoid arthritis?. Expert Opinion on Pharmacotherapy 21:15, pages 1789-1792.
Read now
Read now
Articles from other publishers (24)
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, Mayra Ianhez, Carolina Talhari & Paulo Müller Ramos. (2023) JAK-STAT pathway inhibitors in dermatology. Anais Brasileiros de Dermatologia 98:5, pages 656-677.
Crossref
Crossref
Haizhen A. Zhong & Suliman Almahmoud. (2023) Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors. International Journal of Molecular Sciences 24:7, pages 6023.
Crossref
Crossref
Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis
through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Crossref
Amandine Gouverneur, Jérôme Avouac, Clément Prati, Jean-Luc Cracowski, Thierry Schaeverbeke, Antoine Pariente & Marie-Elise Truchetet. (2022) JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study. European Journal of Clinical Pharmacology 78:12, pages 1981-1990.
Crossref
Crossref
Megha Rachmale, Niraj Rajput, Tarang Jadav, Amit Kumar Sahu, Satyasheel Sharma & Pinaki Sengupta. (2022) High resolution mass spectrometry‐driven metabolite profiling of baricitinib to report its unknown metabolites and step‐by‐step reaction mechanism of metabolism. Rapid Communications in Mass Spectrometry 36:22.
Crossref
Crossref
Jessica M So, Chukwuemeka Umeh, Steven Noriega, Erica Stratton, Mahendra Aseri & Rakesh C Gupta. (2021) Use of Baricitinib in Combination With Remdesivir and Steroid in COVID-19 Treatment: A Multicenter Retrospective Study. Cureus.
Crossref
Crossref
Chun Dang, Yaoheng Lu, Xingyu Chen & Qian Li. (2021) Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway. Frontiers in Immunology 12.
Crossref
Crossref
Shuaihantian Luo, Hai Long & Qianjin Lu. (2020) Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. International Immunopharmacology 89, pages 107028.
Crossref
Crossref
Qichao Bao, Liangying Zhang, Nan Wang, Brian Gabet, Weikang Yang, Xingyang Gao, Qidong You & Zhengyu Jiang. (2020) Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile. ACS Medicinal Chemistry Letters 11:11, pages 2182-2189.
Crossref
Crossref
Essam Ezzeldin, Muzaffar Iqbal, Yousif A. Asiri, Azza A Ali, Prawez Alam & Toqa El-Nahhas. (2020) A Hydrophilic Interaction Liquid Chromatography–Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats. Molecules 25:7, pages 1600.
Crossref
Crossref
Ping Xin, Xiaoyun Xu, Chengjie Deng, Shuang Liu, Youzhi Wang, Xuegang Zhou, Hongxing Ma, Donghua Wei & Shiqin Sun. (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology 80, pages 106210.
Crossref
Crossref
Ying‐Chou Chen, Dae Hyun Yoo, Chang Keun Lee, Ko‐Jen Li, Ji‐Eon Won, Wen‐Shuo Wu, Jinglin Zhong, Claudia Nicolay, Chad Daniel Walls & Yoshiya Tanaka. (2019) Safety of baricitinib in East Asian patients with moderate‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials. International Journal of Rheumatic Diseases 23:1, pages 65-73.
Crossref
Crossref
Christophe RICHEZ, Jacques MOREL, Divi CORNEC, Claire DAÏEN, Philippe GOUPILLE, Estibaliz LAZARO, Thierry LEQUERRÉ, Gaëtane NOCTURNE, Victor de LÉDINGHEN, Benoit Le GOFF, Valérie POURCHER, Clément PRATI, Raphaèle SEROR, Anne TOURNADRE, Marie-Elise TRUCHETET, Jean SIBILIA & Thao PHAM. (2019) Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Joint Bone Spine 86, pages eS2-eS103.
Crossref
Crossref
Katie Bechman, Mark Yates & James B. Galloway. (2019) The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacological Research 147, pages 104392.
Crossref
Crossref
François Chasset & Camille Francès. (2019) Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. Drugs 79:11, pages 1199-1215.
Crossref
Crossref
Mojtaba Abbasi, Mohammad Javad Mousavi, Sirous Jamalzehi, Reza Alimohammadi, Maryam Hasanzadeh Bezvan, Hamed Mohammadi & Saeed Aslani. (2018) Strategies toward rheumatoid arthritis therapy; the old and the new. Journal of Cellular Physiology 234:7, pages 10018-10031.
Crossref
Crossref
Alvin Lee Day & Jasvinder A. Singh. (2019) Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. Drugs & Aging 36:6, pages 493-510.
Crossref
Crossref
Peter C Taylor. (2019) Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology 58:Supplement_1, pages i17-i26.
Crossref
Crossref
Sumit Kunwar, Christopher E. Collins & Florina Constantinescu. (2018) Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clinical Rheumatology 37:10, pages 2611-2620.
Crossref
Crossref
Ian C. Scott, Samantha L. Hider & David L. Scott. (2018) Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?. Drug Safety 41:7, pages 645-653.
Crossref
Crossref
Charles J. Malemud. (2018) The role of the JAK/STAT signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 10:5-6, pages 117-127.
Crossref
Crossref
Zaina T. Al-Salama & Lesley J. Scott. (2018) Baricitinib: A Review in Rheumatoid Arthritis. Drugs 78:7, pages 761-772.
Crossref
Crossref
Marie Febvre-James, Arnaud Bruyère, Marc Le Vée & Olivier Fardel. (2018) The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes. Drug Metabolism and Disposition 46:2, pages 131-140.
Crossref
Crossref
William Vainchenker, Emilie Leroy, Laure Gilles, Caroline Marty, Isabelle Plo & Stefan N. Constantinescu. (2018) JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research 7, pages 82.
Crossref
Crossref